Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol

Author(s): Jeffrey Bulva, Ronald A. Simon*.

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 2 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

The purpose of this section is to educate the reader on how to successfully manage patients with a hypersensitivity reaction to clopidogrel using desensitization protocol based on various published protocols. Additionally, we will define drug desensitization, and describe the possible mechanism of how desensitization may function as alternative medication. The indications/contraindications for desensitization will be reviewed. The different published clopidogrel desensitization protocols will be discussed. Based on those protocols, we recommend a protocol we feel is safe and efficacious.

Clopidogrel is a thienopyridine antiplatelet drug widely used for treatment and also employed for secondary prevention regarding a range of cardiovascular diseases. However, it has been reported to cause hypersensitivity reactions. Ticlopidine is an alternative medication that can be considered when patients have an allergic reaction to clopidogrel. Additionally, ticlopidine is associated with increased risk causing potentially life-threatening adverse reactions to include: Aplastic anemia, reversible neutropenia, and thrombotic thrombocytopenia purpura vs. clopidogrel. Thus, clopidogrel desensitization offers an attractive alternative.

Drug desensitization is defined as causing a temporary state of tolerance to a specific medication responsible for a hypersensitivity reaction. Furthermore, drug desensitization can only be maintained by continuous administration of this drug.

Discussion: The exact immunologically mediated mechanism of how rapid oral desensitization works is not fully understood and yet to be defined. Ultimately desensitization results in causing antigen-specific mast cell tolerance. Various protocols have been published. The length of desensitization ranged from 2 h using 9 doses to 7 h using 15 doses.

Recommendations: Taking the above into account, we recommend using a modification to the protocol that has the largest number of patients to undergo a standardized clopidogrel desensitization. This approach is shorter, as time has immense importance for these patients. Dosing starts at 10 mg dose and with 60 min intervals between doses, this now becomes a 4 h desensitization protocol.

Keywords: Rapid (4 Hour) protocol, clopidogrel desensitization, hypersensitivity reaction, alternative medication, drug desensitization, allergy.

[1]
Cernadas JR, Brockow K, Romano A, et al. General consideration on a rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65: 1357-66.
[2]
Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: Clinical challenges and options for management. Expert Rev Clin Pharmacol 2010; 3: 553-61.
[3]
Ghosh SK, Bandyopadhyay D. Clopidogrel-induced fixed drug eruption. J Eur Acad Dermatol Venereol 2009; 23: 1202-3.
[4]
Pandya N. Clopidogrel bisulfate oral Drug Facts and Comparisons 40 Available from Wolters Kluwer Health, Inc https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852617/ (Accessed on December 5, 2010).
[5]
Patrrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet active drugs: The relationships among dose, effectiveness and side effects: Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(Suppl.): 234-64.
[6]
Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: Management issues. Heart 2004; 90: 14.
[7]
Barrerira P, Cadinha S, Maleiro D, Moreira Da Silva JP. Desensitization to clopidogrel: A tailor-made protocol. Eur Ann Allergy Clin Immunol 2014; 46: 53-5.
[8]
McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
[9]
Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: An adverse drug reaction to clopidogrel loading dose. Int J Cardiol 2004; 95: 333.
[10]
Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever and neutropenia. Mayo Clin Proc 2005; 80: 1386-70.
[11]
von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50(21): 2039-43.
[12]
Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999; 83: 138-9.
[13]
Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopidogrel after a positive skin test. Ann Allergy Asthma Immunol 2005; 94: 132-3.
[14]
Camara MG, Alameda FQ. Clopidogrel (Plavix) desensitization: A case series. Catheter Cardiovasc Interv 2005; 65: 525-7.
[15]
Anderson J. Allergic-like reactions to drugs and other therapeutic agents: Diagnosis and treatment. Humana Press New York 2000; pp. 303-22.
[16]
Patterson R, DeSwarte RD, Greenberger PA, Grammer LC. Drug allergy and protocols for management of drug allergies. N Engl Reg Allergy Proc 1986; 7: 325-42.
[17]
Toogood J. Risk of anaphylaxis in patients receiving beta blocker drugs. J Allergy Clin Immunol 1988; 81: 1-5.
[18]
Lee-Wong M, Gadhvi D, Resnick D. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006; 96: 756-7.
[19]
Walker NE, Fasano MB, Horwitz PA. Desensitization for the management of clopidogrel hypersensitivity: Initial clinical experience. J Invasive Cardiol 2006; 18: 341-4.
[20]
Lang DM. Anaphylactoid and anaphylactic reactions; hazards of β blockers. Drug Saf 1995; 12: 299-304.
[21]
Oppedijk B, Oderkerken DA, van der Wildt JJ, Melissant CF. Rapid oral desensitization procedure in clopidogrel hypersensitivity. Neth Heart J 2008; 16: 21-3.
[22]
Owen P, Garner J, Hergott L, Page RL. Clopidogrel desensitization: Case report and review of published protocols. Pharmacotherapy 2008; 28: 259-70.
[23]
Doshi R, Enoh A, Antonopoulos P, Satter P. A novel, accelerated method of desensitization in a patient with a documented hypersensitivity reaction to clopidogrel. J Cardiol Cases 2010; 1: 158-60.
[24]
MacGlashan D Jr, Lichtenstein LM. Basic characteristics of human lung mast cell desensitization. J Immunol 1982; 139: 501-5.
[25]
Naclerio R, Mizrahi EA, Adkinson NF Jr. Immunologic observation during desensitization and maintenance of clinical tolerance to penicillin. J Allergy Clin Immunol 1983; 71: 294-301.
[26]
Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982; 69: 500-8.
[27]
Durham SR. Allergen immunotherapy (desensitization) for allergic diseases. Clin Med 2006; 6: 348-51.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 2
Year: 2019
Page: [113 - 118]
Pages: 6
DOI: 10.2174/1570161116666181031101930
Price: $58

Article Metrics

PDF: 17
HTML: 1